Both preclinical and clinical studies have shown that targeting the CSF-1/CSF-1R axis can be a promising therapeutic strategy, as using antagonists and mAbs for CSF-1R have great potential to improve the outcome of patients with advanced cancer [60]. The gene discussed is CSF1; the disease is cancer.